Toxicities continue to pose the most significant challenge in the progression of antibody-drug conjugates to the clinic, and with increasing companies entering into the ADC space and tackling toxicity, there is ever-increasing target and indication-competition. Considering the significant clinical setbacks witnessed in 2024, the demand to better understand the translatability of toxicities and develop more tolerable ADCs for achieving future clinical triumphs only grows stronger.

By addressing translational challenges and tackling off-target toxicities, the 2nd ADC Toxicity Summit returned at an imperative time to allow you to prevent, predict and mitigate toxicities to design and develop ADCs with a wider therapeutic index and progress them to the clinic.

In 2024, 80+ of your colleagues from Pfizer, Merck, ImmunoGen, Mersana, Daiichi Sankyo, AbbVie and more, united to discuss shared challenges with ADC toxicities from in vitro all the way to the clinic. Experts in toxicology and translational sciences disclosed never-heard before toxicity data, shared insights into optimal in vivo models for predictability, investigated the use of biomarkers for patient specific ADC prescription and introduced innovative strategies to transform the ADC landscape to increase therapeutic index.

Uniting the leading minds in ADC toxicology, offering actionable insights to unlock the full potential of predicting and mitigating toxicities in ADC development and addressing unmet needs head-on the summit provided three days of highly focused content.